InvestSMART

Peplin Inc. (ASX: PLI) - Announcements

DELISTED - Current share price for PLI : $0.910

ASX company news and announcements for Peplin Inc. (PLI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Peplin Inc. (PLI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Peplin Inc. (PLI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Peplin Inc. (PLI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Peplin Completes Enrolment in its Final Phase 3 Trial for AK 19 Aug 2009 8:48AM $0.570 $0.910 risen by 59.65%
- Appendix 4C - quarterly 31 Jul 2009 4:16PM $0.580 $0.910 risen by 56.90%
- Final Phase 3 Clinical Trial for PEP005 Gel in AK Initiated 23 Jul 2009 9:23AM $0.615 $0.910 risen by 47.97%
- Peplin Initiates Phase 3 Trials for PEP005 Gel in AK 9 Jun 2009 8:27AM $0.600 $0.910 risen by 51.67%
- Peplin`s Phase II AK Trial Results Published in JAAD 28 May 2009 8:28AM $0.670 $0.910 risen by 35.82%
- Positive Results for Peplin`s First Phase III AK Trial 18 May 2009 8:29AM $0.670 $0.910 risen by 35.82%
- Response to ASX Query re Price 4 May 2009 2:25PM $0.730 $0.910 risen by 24.66%
- Appendix 4C - quarterly 30 Apr 2009 4:15PM $0.650 $0.910 risen by 40%
- Peplin`s Positive Phase IIb AK Trial Result Details 6 Mar 2009 9:44AM $0.460 $0.910 risen by 97.83%
- Half year report 13 Feb 2009 5:00PM $0.420 $0.910 risen by 116.67%
- Appendix 4C - quarterly 9 Jan 2009 4:48PM $0.520 $0.910 risen by 75%
- Positive Results for Peplin`s Phase IIb AK Trial 8 Jan 2009 9:14AM $0.465 $0.910 risen by 95.70%
- Peplin Completes Enrolment for its First Phase III AK Trial 16 Dec 2008 12:08PM n/a $0.910 n/a
- Results for Quarter ending 30 September 2008 2 Dec 2008 8:27AM $0.285 $0.910 risen by 219.30%
- Appendix 4C - quarterly 31 Oct 2008 10:39AM $0.460 $0.910 risen by 97.83%
- Peplin initiates Phase III trial for PEP005 Gel in AK 9 Sep 2008 10:08AM $0.410 $0.910 risen by 121.95%
- Preliminary Final Report 29 Aug 2008 12:27PM $0.420 $0.910 risen by 116.67%
- Secures approximately US$24m in additional financing 19 Aug 2008 9:13AM $0.420 $0.910 risen by 116.67%
- Trading Halt 18 Aug 2008 9:59AM n/a $0.910 n/a
- Enrollment complete in Phase IIb AK clinical trial 14 Aug 2008 9:06AM $0.375 $0.910 risen by 142.67%
- Start of Phase IIb AK clinical trial 25 Jun 2008 8:32AM $0.395 $0.910 risen by 130.38%
- Peplin to acquire Neosil, Inc. 10 Jun 2008 2:22PM $0.420 $0.910 risen by 116.67%
- Trading Halt 10 Jun 2008 10:12AM $0.420 $0.910 risen by 116.67%
- Half year report 15 Feb 2008 10:24AM $0.700 $0.910 risen by 30%
- US$15 Million Loan Facility 31 Dec 2007 9:54AM $0.880 $0.910 risen by 3.41%

626 - 650 of 652 results

Page 26 of 27

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.